We are pleased to announce the publication of our special issue dedicated to innovative approaches in the preclinical safety assessment of immunomodulatory biotherapeutics. This milestone has been achieved through a year of dedicated work and collaboration among a diverse group of partners.
The development of this publication was made possible by the invaluable contributions of each collaborator, who brought unique expertise to the project. Together, we explored the role of Adverse Outcome Pathways (AOPs) in shaping the regulatory landscape for advanced therapies, including IL-2 and CAR T-cells.
The special issue, containing all articles, is now available for your review at the following link: Journal of Immunotoxicology, Volume 21, Issue sup1 (2024)
We extend our sincere gratitude to all those involved in this endeavor—your contributions have been essential in realizing this vision.
As we move forward, let us continue to push the boundaries of science and innovation in developing safer and more effective therapies.